Altamira Therapeutics Ltd. (CYTO)
- Previous Close
1.4400 - Open
1.5200 - Bid 1.3900 x 100
- Ask 1.5300 x 100
- Day's Range
1.4001 - 1.5512 - 52 Week Range
1.3500 - 23.6000 - Volume
50,241 - Avg. Volume
1,213,216 - Market Cap (intraday)
3.226M - Beta (5Y Monthly) 2.55
- PE Ratio (TTM)
-- - EPS (TTM)
-16.3000 - Earnings Date Apr 10, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Altamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland and Australia. The company develops and supplies OligoPhore/SemaPhore platforms, which are peptide-based nanoparticle technologies for ribonucleic acid delivery to extrahepatic tissues. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is developing AM-401 for the treatment of KRAS driven cancer; AM-411 for the treatment of rheumatoid arthritis; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase II/III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It also offers Bentrio, a drug-free nasal spray for protection against airborne viruses and allergens. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. The company was founded in 2003 and is based in Hamilton, Bermuda.
altamiratherapeutics.comRecent News: CYTO
Performance Overview: CYTO
Trailing total returns as of 5/13/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CYTO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CYTO
Valuation Measures
Market Cap
3.25M
Enterprise Value
2.68M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.46
Enterprise Value/Revenue
64.93
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-52.83%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-7.27M
Diluted EPS (ttm)
-16.3000
Balance Sheet and Cash Flow
Total Cash (mrq)
617.41k
Total Debt/Equity (mrq)
1.54%
Levered Free Cash Flow (ttm)
-9.18M
Research Analysis: CYTO
Company Insights: CYTO
CYTO does not have Company Insights